Jean Jacques Bienaime, Director at Ascendis Pharma A/S (ASND), bought 400 shares at $236.24 ($95K) on 2026-05-26, disclosed to the SEC on 2026-05-27.
Director Jean Jacques Bienaime purchased 200 shares of Ascendis Pharma for $47,247 on May 26, 2026, marking the largest insider purchase in the company's history. This significant buy suggests insider confidence in the company's long-acting therapies despite recent volatility.
The stock is currently trading at $239.49, down 0.83% over the past five days but up 5.6% over the last month. It sits 4.49% below its 52-week high of $250.74, indicating the recent insider buy comes as the shares pull back from recent highs.
The transaction is itself a catalyst, as it represents the largest insider purchase in the company's history, signaling potential bullish momentum. Additionally, the market will watch for reactions to the company's recent earnings performance, highlighted by the May 15, 2026, analysis noting healthy earnings despite stock hesitation.
A significant risk is the $50 million exit by a fund on May 14, 2026, which could pressure the stock price. Furthermore, the May 15, 2026, report noted that while earnings were healthy, the stock reaction was muted, suggesting potential valuation concerns.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $236.24 | 200 | $47K | 49.7% |
| 2 | $239.37 | 200 | $48K | 50.3% |
| Total | $237.80 avg | 400 | $95K | 100% |
| Filing → |
| KROS | BUY | 2026-07-17 | $11K | — | Filing → |
| KROS | BUY | 2026-06-17 | $10K | — | Filing → |
| IMNM | BUY | 2026-06-09 | $204K | — | Filing → |